Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8049666 | 0.80 | ALDH1A1 (0.41) | ERN1KDM4EMEN1NPC1RAB9A | |
| SCHEMBL8049847 | 0.80 | NPC1 (0.32) | ERN1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL8050518 | 0.76 | — | — | |
| SCHEMBL8039228 | 0.76 | ERN1 (0.38) | ERN1KDM4EKMT2AL3MBTL1TRIM24 | |
| SCHEMBL19737877 | 0.73 | ERN1 (0.47) | ERN1KDM4EMEN1NPC1HSP90AA1 | |
| SCHEMBL543477 | 0.72 | CYP2A6 (0.43) | ERN1KDM4EMEN1NPC1HSP90AA1 | |
| SCHEMBL3704781 | 0.72 | ALDH1A1 (0.38) | ERN1KDM4EMEN1NPC1RAB9A | |
| SCHEMBL19737884 | 0.70 | ERN1 (0.45) | ERN1KDM4EMEN1NPC1HSP90AA1 | |
| SCHEMBL8325747 | 0.70 | RAB9A (0.43) | ERN1KDM4EMEN1NPC1RAB9A | |
| SCHEMBL29111409 | 0.70 | ERN1 (0.56) | ERN1KDM4ERAB9ATRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| WO-2017218960-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | HBB, HBG1, HBG2 | ERN1 2834/4885KDM4E 1603/4885MEN1 1300/4885 |
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | HBB, HBG1, HBG2 | ERN1 2834/4885KDM4E 1603/4885MEN1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.